SCM
TXG icon

Soleus Capital Management’s 10x Genomics TXG Stock Holding History

Soleus Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-951,000
Closed -$21.5M – 108
2024
Q3 		$21.5M Buy
951,000
+232,000
+32% +$4.8M 1.66% 19
2024
Q2 		$14M Buy
+719,000
New +$18.8M 1.23% 31
2023
Q1 		– Sell
-70,000
Closed -$2.55M – 97
2022
Q4 		$2.55M Buy
+70,000
New +$2.29M 0.37% 53
2022
Q2 		– Sell
-106,139
Closed -$8.07M – 83
2022
Q1 		$8.07M Buy
+106,139
New +$9.29M 1.04% 31

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soleus Capital Management's TXG Position: Q4 2024 in Review

Soleus Capital Management sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 951,000 shares — an estimated $21.5M sold.

Soleus Capital Management first reported a position in TXG in Q1 2022 and held it in 4 quarters. The position peaked at $21.5M in Q3 2024. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

  • Soleus Capital Management reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
  • Soleus Capital Management sold 951,000 10x Genomics shares in Q4 2024, an estimated $21.5M.
  • Soleus Capital Management first reported a position in 10x Genomics in Q1 2022 and held it in 4 quarters.
  • Soleus Capital Management's 10x Genomics position peaked at $21.5M in Q3 2024.
  • 273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.